期刊文献+

3.0T磁共振动态增强扫描联合超声检查对不同分子亚型乳腺癌的诊断价值 被引量:19

The value of detecting breast cancer of different molecular subtypes combining ultrasound and dynamic contrast enhancement MRI
原文传递
导出
摘要 目的:研究3.0 T磁共振动态增强扫描联合超声检查对乳腺癌的诊断价值,探讨不同分子亚型乳腺癌的影像特征。方法回顾性分析24例经手术病理证实的乳腺癌患者(30个病灶)的超声和MRI资料,所有患者均为女性,年龄39~69岁,中位年龄55岁;根据雌激素受体、孕激素受体、人表皮生长因子受体-2(HER-2)的表达状态,将乳腺癌分为三阴性、HER-2过表达和Luminal三个亚型,分析不同分子类型乳腺癌的影像表现,如回声/信号、形态、边界、钙化、强化方式、周围组织是否受侵等,重点分析MRI的时间-信号强度曲线(TIC)及超声的Adler血供分型。结果根据乳腺癌分子亚型的标准,三阴性型占3.3%(1/30);Her-2过表达型占20.0%(6/30),Luminal型占76.7%(23/30)。术前超声单独诊断乳腺癌的准确率为76.7%(23/30),MRI单独诊断乳腺癌的准确率为86.7%(26/30),联合超声、MRI诊断乳腺癌的准确率为96.7%(29/30)。MRI的TIC以Ⅱ型、Ⅲ型居多,分别为18/30(60%)、12/30(40%),超声 Adler 血供以Ⅱ型居多(18/30,60%);MRI的TIC对Her-2过表达及Luminal乳腺癌两种分子分型有统计学意义(P<0.05)。结论不同分子类型乳腺癌的影像学征象各具特点;联合磁共振动态增强扫描与超声检查对乳腺癌的检出准确率均高于单独任一检查方法。 Objective To evaluate the diagnostic capability of detecting breast cancer combining ultrasound and dynamic contrast enhancement MRI and to investigate the ultrasonic and MRI features of breast cancers of different molecular subtypes.MethodsUltrasonic and MRI data of 24 patients (30 lesions) with breast cancer confirmed by pathology were retrospectively analyzed. All patients were female, aged 39-69 years, with a median age of 55 years. According to the expression of estrogen receptors, progesterone receptor and human epidermal growth factor receptor-2 (HER-2), the tumors were classified into triple-negative, HER-2 over expressed and luminal subtypes. The imaging features of different molecular subtypes breast cancers, such as the echo/signal, border, calcification, blood supply of tumor and the changes of surrounding tissue of tumors, were analyzed, especially time-signal intensity curve type in MRI and Alder blood supply type.Results There were one case of triple-negative (1/30), 6 cases of HER-2 over expressed (6/30) and 23 cases of Luminal subtypes (23/30). Diagnostic accuracy rate of breast cancer by ultrasound was 76.7%, and 86.7% by MRI, and both of them were 96.7%. There were statistical differences in TIC curve between HER-2 and Luminal subtypes (P〈0.05).Conclusion Ultrasonic and MRI imaging features of different molecular subtypes breast cancers have some characteristics. Diagnostic accuracy rate of breast cancer combined ultrasound with MRI is higher than either one.
出处 《中华临床医师杂志(电子版)》 CAS 2014年第16期49-52,共4页 Chinese Journal of Clinicians(Electronic Edition)
基金 2013年广州市医药卫生科技项目:功能磁共振成像联合血清VEGF对乳腺癌治疗疗效的定量评估(20131A011024)
关键词 乳腺肿瘤 超声 磁共振成像 Breast neoplasms Ultrasonography Magnetic resonance imaging
  • 相关文献

参考文献12

  • 1彭康强,黄子林,谢传淼,陈林,欧阳翼,郑庆生,张岩,何浩强,吴沛宏.乳腺动态增强MRI及其后处理技术在乳腺肿瘤诊断中的应用[J].癌症,2009,28(5):549-554. 被引量:11
  • 2贾晓红,金正吉,张晓晓,朱樱,詹维伟.不同分子亚型乳腺癌超声及MRI特征[J].中国医学影像技术,2013,29(8):1297-1300. 被引量:12
  • 3Foulkes WD, Smith IE, Reis-Filho JS. Triple-negate breast cancer[J]. N Engl J Med, 2010, 363(20): 1938-1948.
  • 4刘佩芳,张淑平,邵真真,鲍润贤.磁共振成像对形态学表现为良性特征的乳腺恶性肿瘤诊断价值[J].磁共振成像,2012,3(2):98-108. 被引量:33
  • 5朱风婷,钟锦双,许桂晓,等.比较DWI与动态增强扫描在诊断乳腺良恶性病变中的差异[J/CD].中华临床医师杂志:电子版,2013.7(9):4117-4119.
  • 6Wojeinski S, Soliman AA, Schmidt J, et al. Sonographic features of triple-negative and non-triple-negative breast cancer[J]. J Ultrasound Med, 2012, 31(10): 1531-1541.
  • 7Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma: a phenotypieally distinct entity[J]. Arch Pathol Lab Meal, 2010, 134(1): 130-133.
  • 8Sen BK, Pisano ED, Kuzimak CM, et al. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas[J]. Aead Radiol, 2006, 13(10): 1211-1218.
  • 9Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer[J]. Ann Oncol, 2012, 23 Suppl 6: vi23-29.
  • 10Sawaki M, Ito Y, Tada K, et al. Efficacy and safety of trastuzuraab as a single agent in heavily pretreated patients with HER-2/nen- overexpressing metastatic breast cancer[J]. Tumori, 2004, 90(1): 40-43.

二级参考文献67

  • 1刘佩芳,尹璐,牛昀,杨建梅,鲍润贤.原发性乳腺淋巴瘤X线表现及与病理相关性探讨[J].中华放射学杂志,2005,39(1):46-49. 被引量:27
  • 2娄路馨,彰俊杰,时高峰.MR动态增强及减影成像对乳腺良恶性疾病的诊断价值[J].临床放射学杂志,2007,26(2):148-152. 被引量:25
  • 3赵斌,王光彬.重视MRI在乳腺疾病中的重要作用[J].医学影像学杂志,2007,17(2):109-110. 被引量:11
  • 4Fischer U, Kopka L, Grabbe E.Breast Carcinoma : effect of preoperative contrast-enhanced MR imaging on the therapeutic approach [J]. Radiology, 1999,213(3):881- 888.
  • 5Helbich TH, Becherer A, Trattnig S, et al. Differentiation of benign and malignant breast lesions: MR imaging Tc-99m sestamibi scintimammography [ J ]. Radiology, 1997,202 (2) : 421-429.
  • 6Kuhl C, Mielcareck P, Klaschnik S et al. Dynamic breast MR imaging are signal intensity time course data useful for differential diagnosis of enhancing lesions? [J]. Radiology, 1999,211(1) : 101-110.
  • 7Zheng G, Peng F, Ding R, et al. Identification of proteins re- sponsible for the multiple drug resistance in 5-fluorouracil-induced breast Cancer cell using proteomics analysis. J Cancer Res Clin Oncol, 2010,136(10) : 1477-1488.
  • 8Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N EnglJ Med, 2010,363(20):1938-1948.
  • 9Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Canc- er Network. Cancer, 2012,118(22):5463-5472.
  • 10Sawaki M, Ito Y, Tada K, et al. Efficacy and safety of trastu- zumab as a single agent in heavily pretreated patients with HER- 2/neu-overexpressing metastatic breast cancer. Tumori, 2004,90 (1) :40-43.

共引文献68

同被引文献133

  • 1Foulkes WD, Smith IE, Reis-Filho JS. Triple-negate breast cancer[J]. N Engl J Med, 2010, 363(20): 1938-1948.
  • 2朱风婷,钟锦双,许桂晓,等.比较DWI与动态增强扫描在诊断乳腺良恶性病变中的差异[J/CD].中华临床医师杂志:电子版,2013.7(9):4117-4119.
  • 3Wojeinski S, Soliman AA, Schmidt J, et al. Sonographic features of triple-negative and non-triple-negative breast cancer[J]. J Ultrasound Med, 2012, 31(10): 1531-1541.
  • 4Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma: a phenotypieally distinct entity[J]. Arch Pathol Lab Meal, 2010, 134(1): 130-133.
  • 5Sen BK, Pisano ED, Kuzimak CM, et al. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas[J]. Aead Radiol, 2006, 13(10): 1211-1218.
  • 6Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer[J]. Ann Oncol, 2012, 23 Suppl 6: vi23-29.
  • 7Sawaki M, Ito Y, Tada K, et al. Efficacy and safety of trastuzuraab as a single agent in heavily pretreated patients with HER-2/nen- overexpressing metastatic breast cancer[J]. Tumori, 2004, 90(1): 40-43.
  • 8Munjal K, Ambaye A, Evans MF, et al. analysis ofER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients[J]. Asian Pac J Cancer Prey, 2009, 10(5): 773-778.
  • 9Roland B. Sennerstam,Hans Wiksell,Kai-Uwe Schaessburger.Breast Cancer and Clinical Outcome Among Women Over 60 Years of Age A Plead for More Screening and Alternative Treatments. ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY . 2012
  • 10Santamaría Gorane,Velasco Martín,Bargalló Xavier,Caparrós Xavier,Farrús Blanca,Luis Fernández Pedro.Radiologic and pathologic findings in breast tumors with high signal intensity on T2-weighted MR images. Radiographics : a review publication of the Radiological Society of North America, Inc . 2010

引证文献19

二级引证文献111

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部